
Release date: 2026-01-30 16:27:21 Article From: Lucius Laos Recommended: 16
Anagrelide is indicated to reduce the risk of blood clots in patients with thrombocythemia (an abnormally high platelet count in the blood). Its mechanism of action is to inhibit platelet production in the body.
Report the following side effects to your medical team as soon as possible:
Allergic reactions: Skin rash, pruritus, urticaria, swelling of the face, lips, tongue or throat
Bleeding: Bloody or black tarry stools, vomiting blood or brown material resembling coffee grounds, red or dark brown urine, small red or purple spots on the skin, unusual bruising or bleeding
Cardiac rhythm changes: Tachycardia or irregular heartbeat, dizziness, feeling faint or lightheaded, chest pain, dyspnea
Lung injury: Shortness of breath or difficulty breathing, cough, hemoptysis, chest pain, fever
Pulmonary hypertension: Shortness of breath, chest pain, tachycardia or irregular heartbeat, feeling faint or lightheaded, fatigue, swelling of the ankles or feet
Anagrelide may cause serious health problems, with a significantly increased risk in specific populations. If you have concerns about this, consult your doctor or pharmacist for alternative treatment options.
Cases of cardiac disorders and cardiac rhythm abnormalities have been reported in patients taking anagrelide, with a higher incidence in patients with a history of heart disease or at high risk of heart disease. Severe hepatic disease can elevate the plasma concentration of anagrelide, thereby increasing the risk of cardiac adverse events. Disclose your complete medical history to healthcare providers, including cardiac conditions, as well as all medications you are currently taking.
Concomitant use of anagrelide with aspirin will greatly increase the risk of severe bleeding; the risk also rises when combined with other medications that increase bleeding tendency. Disclose all medications you are taking to healthcare providers for assessment of drug-drug interactions. Continuous monitoring for signs and symptoms of bleeding is required, including progressively enlarging ecchymoses, gingival bleeding, black tarry stools, hematuria, etc. Contact healthcare providers immediately if any of the above symptoms occur.
Serious pulmonary diseases have been reported with anagrelide use, and this adverse reaction may occur at any time during treatment. Inform healthcare providers promptly of any changes in respiratory status, including worsening dyspnea. If healthcare providers suspect lung injury, treatment may be temporarily discontinued, and related symptoms usually improve after drug withdrawal.
1. Store this medication in a tightly sealed container at room temperature, protected from heat, moisture and direct sunlight. Do not freeze.
2. Keep it out of the reach of children.
3. Do not retain expired or unused medication.
4. Consult your doctor for instructions on the proper disposal of unused medication.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:802025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3732024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:712025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:932025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:872025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1022025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:992025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:992025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: